Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.
Sherene LoiChristos S KarapetisNicole McCarthyCatherine OakmanAndrew RedfernMichelle WhiteMustafa KhasrawDinesh Chandra DovalVinod GoreMahmood AlamJustin BinkoDongrui Ray LuSindy KimFrances BoylePublished in: Asia-Pacific journal of clinical oncology (2021)
In an expanded access setting in Australia and India, palbociclib plus letrozole was well tolerated in patients with HR+/HER2- ABC, with a safety profile consistent with previous reports.
Keyphrases
- epidermal growth factor receptor
- polycystic ovary syndrome
- early breast cancer
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- metastatic breast cancer
- insulin resistance
- bone mineral density
- type diabetes
- induced pluripotent stem cells
- adipose tissue
- breast cancer risk
- metabolic syndrome
- young adults
- body composition
- drug induced